
Opinion|Videos|October 15, 2024
Patient Profile 1: A 70-Year-Old Man With PSMA-Positive mCRPC
Author(s)Oliver Sartor, MD
Key Takeaways
Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential radioligand therapy, considering factors such as disease progression, previous treatments, and overall health status in tailoring management strategies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
4
Microbial dysbiosis may predict response to CBM588 in mRCC
5












